QCLS

Q/C Technologies Inc

Apr 08 • 04:00PM ET

3.61

+0.14 4.03 %

Technology • Computer Hardware • USA • NASD

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN VRTX REGN

Index	-	P/E	-	EPS (ttm)	-149.63	Insider Own	6.30%	Shs Outstand	7.85M	Perf Week	4.64%
Market Cap	28.35M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	7.36M	Perf Month	-11.30%
Enterprise Value	25.49M	PEG	-	EPS next Q	-	Inst Own	9.59%	Short Float	20.12%	Perf Quarter	-17.20%
Income	-11.56M	P/S	-	EPS this Y	-	Inst Trans	22.97%	Short Ratio	1.32	Perf Half Y	-26.33%
Sales	0.00M	P/B	0.76	EPS next Y	-	ROA	-25.45%	Short Interest	1.48M	Perf YTD	-9.52%
Book/sh	4.76	P/C	2.83	EPS next 5Y	-	ROE	-40.64%	52W High	33.56 -89.24%	Perf Year	-86.28%
Cash/sh	1.27	P/FCF	-	EPS past 3/5Y	24.22% 50.65%	ROIC	-54.23%	52W Low	2.50 44.40%	Perf 3Y	-99.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.98% 9.03%	Perf 5Y	-99.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	89.10%	Oper. Margin	-	ATR (14)	0.35	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.71	EPS Q/Q	97.74%	SMA20	-1.73%	Beta	2.17	Target Price	32.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.84%	Rel Volume	0.18	Prev Close	3.47
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-36.95%	Avg Volume	1.12M	Price	3.61
IPO	Jul 24, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	-79.41% -14.63%	Trades		Volume	205,193	Change	4.03%

Mar-18-26 09:15AM	Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference (GlobeNewswire)
Jan-20-26 09:15AM	Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors (GlobeNewswire)
Dec-09-25 09:15AM	Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli (GlobeNewswire)
Oct-30-25 09:15AM	Q/C Technologies Introduces Proprietary qc-LPU100 Brand of Quantum-Class Laser Processing Units (GlobeNewswire) -11.05%
Oct-16-25 09:15AM	Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives (GlobeNewswire) +16.03%
09:15AM	Loading…
Sep-25-25 09:15AM	Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS" (Business Wire) -9.62%
Sep-24-25 09:15AM	TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing (Business Wire) +48.15%
Sep-17-25 09:24AM	TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire)
Sep-08-25 09:15AM	TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +14.24%
Sep-04-25 09:15AM	TNF Pharmaceuticals Announces Closing of $7 Million Private Placement (Business Wire)
Sep-02-25 09:20AM	PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications (Business Wire) -21.33%
09:15AM	TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications (Business Wire)
Aug-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -21.59%
Aug-28-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -31.56%
09:15AM	TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance (Business Wire)
10:30AM	Loading…
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +15.53%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.72%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +9.60%
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -16.78%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.86%
Aug-20-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-19-25 05:20PM	TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation (Business Wire) -6.97%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-12-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.53%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -5.84%
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.74%
Jul-31-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.72%
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -19.04%
10:30AM	Loading…
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +23.52%
Jul-24-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +17.75%
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +47.89%
Jul-16-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Jun-24-25 09:15AM	TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease (Business Wire)
May-08-25 09:20AM	TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists (Business Wire)
Apr-22-25 09:15AM	TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development (Business Wire)
Apr-16-25 09:15AM	TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025 (Business Wire) -9.00%
Mar-18-25 09:25AM	TNF Pharmaceuticals presents isomyosamine data (TipRanks)
Mar-17-25 09:15AM	TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia (Business Wire) +5.49%
Mar-05-25 09:00AM	TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 (Business Wire)
Feb-25-25 09:20AM	TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor (Business Wire) +5.55%
Jan-29-25 09:15AM	TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment (Business Wire) -9.83%
Jan-15-25 09:15AM	TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion (Business Wire) -20.27%
Dec-19-24 09:15AM	TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs (Business Wire)
Dec-09-24 09:00AM	TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference (Business Wire) +13.71%
Oct-02-24 09:10AM	TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market (Business Wire) +18.62%
Aug-21-24 09:00AM	TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline (Business Wire) -11.39%
Jul-24-24 09:05AM	TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today (Business Wire) +9.89%
Jul-22-24 09:00AM	MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. (Business Wire)
Jul-15-24 07:52AM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Jun-17-24 09:00AM	MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer (Business Wire)
May-21-24 09:00AM	PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease (Business Wire) -12.18%
09:00AM	MyMD Pharmaceuticals Secures Strategic Investments (Business Wire)
May-17-24 03:52PM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) +7.31%
Apr-09-24 08:21AM	Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today? (InvestorPlace)
Mar-05-24 09:15AM	MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (Business Wire)
Feb-13-24 11:45AM	MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (Business Wire) -14.49%
Dec-29-23 12:45PM	MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug (ACCESSWIRE)
Dec-06-23 09:15AM	MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis (Business Wire) -5.75%
Oct-19-23 09:00AM	MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain (Business Wire)
Oct-04-23 07:30AM	MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 (Business Wire)
Aug-14-23 08:30AM	FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application (IND) for Phase 2 Study of oral TNF- inhibitor MYMD-1® in Rheumatoid Arthritis (RA) (Business Wire) -7.64%
Aug-02-23 08:30AM	MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results (Business Wire)
Jul-31-23 09:00AM	MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty (Business Wire) +31.82%
Apr-12-23 08:30AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.54%
Mar-20-23 08:55AM	MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1® in Rheumatoid Arthritis (Business Wire) -5.00%
Mar-08-23 08:30AM	MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls (Business Wire)
Mar-02-23 08:30AM	MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical (Business Wire) +5.62%
Feb-28-23 08:30AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting (Business Wire)
Feb-21-23 08:45AM	MyMD Announces $15 Million Offering with Existing Investors (Business Wire) -7.32%
Dec-06-22 09:40AM	ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 (Business Wire) -9.74%
Nov-17-22 08:00AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress (Business Wire)
Nov-14-22 08:00AM	MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research (Business Wire) -5.96%
Sep-20-22 08:00AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -6.25%
Aug-30-22 08:30AM	MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound (Business Wire) -7.27%
Aug-03-22 09:45AM	Data Showing MyMD Pharmaceuticals MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences (Business Wire)
Jul-29-22 09:19AM	Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders? (Simply Wall St.) +5.79%
Jul-26-22 07:30AM	MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -11.44%
Jul-12-22 09:30AM	MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions (Business Wire) +17.10%
Jun-21-22 10:30AM	MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire)
Apr-05-22 09:15AM	MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.79%
Mar-24-22 09:26AM	MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24 (Business Wire)
Feb-23-22 09:15AM	MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -9.49%
Feb-20-22 08:37AM	We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate (Simply Wall St.)
Feb-08-22 09:15AM	MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -5.13%
Feb-07-22 08:38PM	NorthRock Partners, LLC Buys PepsiCo Inc, iShares MSCI EAFE ETF, iShares MSCI Emerging Markets ... (GuruFocus.com)
Jan-05-22 09:15AM	MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia (Business Wire) -5.26%
Dec-29-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia (Business Wire)
Dec-16-21 10:50AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Dec-01-21 10:05AM	MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021 (Business Wire)
Nov-23-21 09:25AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan (Business Wire)
Nov-18-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (Business Wire) -9.76%
Nov-16-21 09:25AM	MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -11.75%
Nov-15-21 09:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
Oct-26-21 10:30AM	MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation (Business Wire)
Oct-19-21 10:30AM	MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 (Business Wire) +6.56%
Oct-05-21 10:00AM	MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 (Business Wire)
Sep-22-21 11:00AM	MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD (Business Wire)
Sep-13-21 10:00AM	MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -9.30%

Q/C Technologies, Inc. engages in the provision of energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. The company was founded in 1989 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QCLS

Q/C Technologies Inc

Upgrade your Finviz experience